Wednesday, November 13, 2013 6:06 PM PST
Twitter can be a great source of information for an ever-increasing number of investors. But as with most technological inventions, it can be misused. The back and forth yesterday on two stocks with large moves was a case in point. Sarepta Therapeutics Inc (NASDAQ:SRPT) traded down 62.5%, effectively wiping out all of the gains that the company's share price had made during the past year. Another company, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) soared 91% on a positive recommendation for approval by the FDA...
Wednesday, November 6, 2013 6:01 AM PST
In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a potentially huge binary event from Zalicus, Inc. (ZLCS); a big board biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain which could, according to some of the analysts who cover the stock, see share prices soaring from current levels to somewhere between $12 and $18 per share depending on pending clinical data which is set to be released...
Thursday, October 31, 2013 12:13 AM PDT
Zalicus (ZLCS) Selected by Panel of Experts over hundreds of others to present at Therapeutic Area Partnerships Conference November 18-20, 2013 in Boston
Tuesday, October 29, 2013 4:09 AM PDT
Our Seeking Alpha followers know that one of our favorite times to buy and trade stocks is when they may have hit technical and fundamental bottoms. We are constantly scanning for "bottom bouncers" and historically have had particularly good fortune with healthcare stocks that have upcoming catalysts or news. We called our latest successful bottom bounce for CEL-SCI (CVM) in our last Seeking Alpha article after surviving a de-listing notice, a reverse stock split and a capital raise. That stock has traded more...
Wednesday, October 2, 2013 10:50 PM PDT
A joint press release on August 7th from Martha Stewart Living Omnimedia (NYSE: MSO) and Inergetics, Inc. (OTCBB: NRTI) introduced Martha Stewart Essentials, a new line of “Whole-Food-Based, high quality supplements,” made specifically for woman. The line consists of six products made specifically to address the health needs of woman including products for Hair, Skin and Nails, Bone Support and Menopause Support. The press release said the products would be on retail shelves September 15. There has not been...
Tuesday, October 1, 2013 3:02 AM PDT
Baker Bros. Advisors is a ~5 BB small & micro-cap focused biotechnology fund run by Julian Baker and Felix Baker. The fund has generated exceptional returns this year – largely due to a huge long position they started in ACADIA Pharmaceuticals (NASDAQ: ACAD) (YTD = +481%). While the fund is quite secretive, it is required file SEC Form 13F which allows the public to see which particular biotech stocks are being accumulated.
Wednesday, September 4, 2013 10:19 AM PDT
Shares of Amarin Corporation (NASDAQ: AMRN) finally seem to be recovering from a prolonged selloff in July and August – possibly on the “adequate” prescription sales data that has recently been coming through for the company’s flagship drug Vascepa. Shares bottomed at a newly-made 52-week low of $5.12/share before rallying (strongly) in the last few weeks. This recent rally fought against the broader bearish trend in the pharmaceutical space as well as the broader market. This is an encouraging turn of events...
Monday, August 26, 2013 10:16 AM PDT
Ampion (also referred to as DMI 9523 in some of the literature) is a small-molecule made up of two amino acids that are derived from albumin, which is the main constituent of plasma in humans. Ampion has been shown to be effective in causing a reduction of pro-inflammatory molecules, as well as inhibition of transcription factors involved in inflammation. The overall profile of the biologic is unique, and distinguished in comparison to other NSAIDs. Since the safety profile has been well established in previous studies, it’s especially important that the finalized version of the trial establishes its efficacy and clinical utility ahead of the FDA’s final review.
Thursday, August 22, 2013 10:45 AM PDT
An interview with PLC Systems CEO Mark Tauscher about the company's product RenalGuard and its use in the clinical setting
Wednesday, August 21, 2013 12:03 AM PDT
Going forward, we should see serious interest in SL-401, and STML due to its very strong post-IPO performance. Biotech investors have also been very interested in quality blood cancer drugs this year, which has bumped up the valuation of some of the larger biotech names in recent months. This bodes well for Stemline and other companies targeting rare cancer indications, and especially those with novel approaches.Investors should also not forget about less often discussed program SL-701, which targets glioblastoma multiforme (GBM) and other gliomas (brain cancers) and is approaching late-stage development as well.